Anthracycline-Induced Cardiotoxicity
Authors: Kesavan Shan
Journal: Annals of Internal Medicine (1997)

Letters15 May 1997Anthracycline-Induced CardiotoxicityKesavan Shan, MD, A. Michael Lincoff, MD, and James B. Young, MDKesavan Shan, MDBaylor College of Medicine, Houston, TX 77030The Cleveland Clinic Foundation, Cleveland, OH 44195Search for more papers by this author, A. Michael Lincoff, MDBaylor College of Medicine, Houston, TX 77030The Cleveland Clinic Foundation, Cleveland, OH 44195Search for more papers by this author, and James B. Young, MDBaylor College of Medicine, Houston, TX 77030The Cleveland Clinic Foundation, Cleveland, OH 44195Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-10-199705150-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Steinherz for highlighting data on the long-term follow-up of patients after anthracycline treatment. Nevertheless, there remains a concerning lack of prognostic information from adequately powered controlled studies assessing cardiac function in patients more than 10 years after anthracycline therapy. For example, in one of Steinherz and colleagues' reports [1], no control group was used for comparison; because of the abstract format of the report, few specific clinical details are available on the patients studied. In our review we attempted to concentrate on follow-up studies of anthracycline recipients that were as detailed as possible in order ...References1. Steinherz LJ, Steinherz PG, Sklar C, Wollner N, Tan C. Cardiac status of 42 patients ≥ 15 years post anthracycline therapy. Med Pediatr Oncol. 1994;23:176. Google Scholar2. Steinherz LJ, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for the treatment of acute lymphoblastic leukemia in children at increased risk of early relapse: The MSK-New York-II protocol. Cancer. 1993; 72:3120-30. Google Scholar3. Beanlands RS, Shaikah NA, Wen HU, Dawood F, Ugnat AM, McLaughlin PR, et al. Alterations in fatty acid metabolism in adriamycin cardiomyopathy. J Mol Cell Cardiol. 1994; 26:109-19. Google Scholar4. Kawaski N, Lee JD, Tsubokawa A, Yamamoto M, Shimizu H, Ueda T, et al. Myocardial glycolytic and fatty acid metabolism during progression of adriamycin (ADR)-induced heart failure. J Am Coll Cardiol. 1995. Google Scholar5. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. Oncology. 1988; 45:242-6. Google Scholar Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine, Houston, TX 77030The Cleveland Clinic Foundation, Cleveland, OH 44195 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTargeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages – A promising cancer immunotherapyA Critical Risk-Benefit Assessment Argues Against the Use of Anthracyclines in Induction Regimens for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia 15 May 1997Volume 126, Issue 10Page: 827-828KeywordsCardiomyopathiesCardiovascular therapyChildrenFatty acidsHeartLongitudinal studiesPatientsPhosphatesPilot studies Issue Published: 15 May 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...